Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Aether Industries Limited (AETHER.NS)
Surat, IN
Aether Industries Limited operates internationally and within India, specializing in the production and distribution of sophisticated chemical intermediates and specialized chemical compounds. The company's comprehensive product lineup features items such as 4-(2-Methoxyethyl) phenol (4MEP), N-Octyl-D-glucamine (NODG), ortho tolyl benzo nitrile (OTBN), thiophene-2-ethanol (T2E), 1-2-(2Hydroxyethoxy) ethyl piperazine (HEEP), delta-valerolactone (DVL), and bifenthrin alcohol. These chemicals are supplied to a broad array of sectors, including pharmaceuticals, agrochemicals, material science, protective coatings, advanced photography, various additive applications, and the oil and gas industry. Furthermore, Aether Industries extends its expertise through contract research and manufacturing services. Established in 2013, the company's primary operations are situated in Surat, India.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.95% | -3.11% | -8.43% | +12.35% | +18.07% | +26.21% | +48.17% | +19.34% | +40.17% | +40.17% | +40.17% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 4 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals - Specialty: +4.7%+38.0% ★ Q1'26: +26.1% (vs Q1'25)
-
EPS growth Chemicals - Specialty: +13.2%+38.4% ★ Q1'26: +7.7% (vs Q1'25)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%+2.7% Q1'26: -66.9% (vs Q1'25)
-
EBIT margin Chemicals - Specialty: +8.8%+25.6% ★ Q1'26: +21.1% (vs Q1'25)
-
ROIC Chemicals - Specialty: +5.6%+7.7% ★ Q1'26: +7.0% (vs Q1'25)
-
Share dilution Chemicals - Specialty: +0.1%+0.1% Q1'26: -0.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×1.26× Q1'26: 1.38× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 4 Rev. Ana. 4 EPS Ana. |
Mar 2027 3 Rev. Ana. 2 EPS Ana. |
Mar 2028 4 Rev. Ana. 4 EPS Ana. |
Mar 2029 2 Rev. Ana. 2 EPS Ana. |
Mar 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
5.93B
est: 5.89B (+0.6%)
|
6.54B
est: 6.63B (-1.2%)
|
6.00B
est: 6.17B (-2.8%)
|
8.41B
est: 8.24B (+2.0%)
|
11.57B
11.38B – 11.86B
+40.5% YoY
|
15.45B
15.24B – 15.85B
+33.5% YoY
|
19.85B
18.83B – 21.13B
+28.5% YoY
|
25.18B
25.11B – 25.25B
+26.8% YoY
|
30.58B
29.51B – 32.04B
+21.4% YoY
|
| EBITDA |
1.70B
est: 1.56B (+8.6%)
|
1.87B
est: 1.76B (+6.6%)
|
1.30B
est: 1.71B (-23.9%)
|
2.39B
est: 2.29B (+4.7%)
|
3.21B
3.16B – 3.29B
+40.5% YoY
|
4.29B
4.23B – 4.40B
+33.5% YoY
|
5.51B
5.23B – 5.87B
+28.5% YoY
|
6.99B
6.97B – 7.01B
+26.8% YoY
|
8.49B
8.19B – 8.89B
+21.4% YoY
|
| EBIT |
1.55B
est: 1.34B (+16.0%)
|
1.66B
est: 1.51B (+10.5%)
|
939.27M
est: 1.44B (-34.7%)
|
1.98B
est: 1.92B (+3.2%)
|
2.70B
2.65B – 2.76B
+40.5% YoY
|
3.60B
3.55B – 3.69B
+33.5% YoY
|
4.62B
4.39B – 4.92B
+28.5% YoY
|
5.87B
5.85B – 5.88B
+26.8% YoY
|
7.12B
6.87B – 7.46B
+21.4% YoY
|
| Net Income |
1.09B
est: 1.27B (-14.4%)
|
1.30B
est: 1.39B (-6.4%)
|
824.90M
est: 826.08M (-0.1%)
|
1.58B
est: 1.76B (-9.7%)
|
2.38B
2.23B – 2.54B
+35.8% YoY
|
2.90B
2.85B – 3.00B
+21.6% YoY
|
3.81B
3.47B – 4.07B
+31.6% YoY
|
4.81B
4.64B – 4.82B
+26.0% YoY
|
5.80B
5.54B – 6.16B
+20.7% YoY
|
| SGA |
271.67M
est: 314.41M (-13.6%)
|
351.45M
est: 353.61M (-0.6%)
|
389.69M
est: 408.28M (-4.6%)
|
434.88M
est: 545.05M (-20.2%)
|
765.71M
753.12M – 784.81M
+40.5% YoY
|
1.02B
1.01B – 1.05B
+33.5% YoY
|
1.31B
1.25B – 1.40B
+28.5% YoY
|
1.67B
1.66B – 1.67B
+26.8% YoY
|
2.02B
1.95B – 2.12B
+21.4% YoY
|
| EPS |
9.67
est: 9.60 (+0.7%)
|
10.47
est: 10.50 (-0.3%)
|
6.31
est: 6.23 (+1.3%)
|
11.95
est: 12.63 (-5.4%)
|
17.50
16.80 – 19.10
+38.5% YoY
|
22.05
21.48 – 22.62
+26.0% YoY
|
28.85
26.13 – 30.66
+30.8% YoY
|
35.60
34.91 – 36.29
+23.4% YoY
|
43.70
41.71 – 46.41
+22.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-20 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-19 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Matthews India Active ETF INDE INDE | 0.39% | 69.5K | 0.79% |
| 2 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.04% | 250.3K | 0.65% |
| 3 | WisdomTree India Earnings Fund EPI | 0.00% | 39.6K | 0.84% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| James W. Ringer | Chief Technology Officer | 20M | — |
| Faiz Arif Nagariya | Chief Financial Officer | 7M | male |
| Chitrarth Rajan Parghi | Company Secretary & Compliance Officer | 970.0K | male |
| Purnima Ashwin Desai | Whole-time Director | — | female |
| Aman Ashwinbhai Desai | Whole-time Director | — | — |
| Rohan Ashwin Desai | Whole-time Director | — | male |
| Ashwin Jayantilal Desai | MD & Director | — | male |
| Kushal Doshi | Lead Investor Relations | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AETHER.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
